Reports Q2 revenue $5.249M, consensus $11.09M. “At Selecta, we remain committed to SEL-212, a potentially unique and differentiated once monthly uricase based treatment option for patients with chronic refractory gout, which we believe has the potential to exceed $700 million in peak sales in the U.S.,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. “Our actions today will allow us to preserve capital and maintain our stockholders’ interest in this asset without the dilution that would have been required to support the development of our pipeline assets over the long term. While we believe that our pipeline programs represent great potential, we intend to pursue partnership opportunities to advance the balance of our portfolio and maximize their value.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SELB: